FDA reiterated it is up to Congress to create a legal status for CBD and other hemp-derived cannabinoids. The FDA cited CBD’s inherent risk profile and insists it can take the harm reduction approach only if Congress enacts legislation for a specific new regulatory framework.
Principle Deputy Commissioner for Office of the FDA Commissioner released statement regarding Agency’s approach towards cannabidiol CBD and application in food and drug industry. FDA convened internal working group to explore potential regulatory pathways for CBD products.